/
Oncology
Urinary Bladder Neoplasms
21
Pipeline Programs↗
13
Active Trials↗
12
Companies Involved↗
Urinary Bladder Neoplasms is an emerging landscape with 21 programs across 12 companies. The most active players are Johnson & Johnson, Eli Lilly. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 18
Phase 310
Approved
No programs
Analysis
Modality Breakdown
68%
Small molecule
13 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 90% of 21 pipeline programs.
Analysis
Trial Status
18
clinical trials
Active, not recruiting5 · 28%
Not yet recruiting4 · 22%
Recruiting4 · 22%
Completed3 · 17%
Terminated1 · 6%
Available1 · 6%
Clinical Trials
Trial Activity
18 trials
Toripalimab With Sequential Intravesical Gemcitabine-Mitomycin C Versus Toripalimab Alone for the Treatment of BCG-Unresponsive/-Intolerant High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized, Multicenter, Phase 2 Study
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07189793·106 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)